Daneng Li

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    AstraZeneca
    Topic:
    HCC
    Date added:
    03/17/2022
    Date updated:
    12/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Grant Or Contract
    Ineligible company:
    Brooklyn ImmunoTherapeutics
    Topic:
    HCC
    Date added:
    03/17/2022
    Date updated:
    12/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Adagene
    Topic:
    HCC
    Date added:
    03/17/2022
    Date updated:
    12/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Eisai
    Topic:
    HCC
    Date added:
    03/17/2022
    Date updated:
    12/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Exelixis
    Topic:
    HCC
    Date added:
    03/17/2022
    Date updated:
    12/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Genentech
    Topic:
    HCC
    Date added:
    03/17/2022
    Date updated:
    12/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Ipsen
    Topic:
    Pancreas, NET
    Date added:
    03/17/2022
    Date updated:
    12/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Merck
    Topic:
    HCC
    Date added:
    03/17/2022
    Date updated:
    12/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Servier
    Topic:
    BTC
    Date added:
    03/17/2022
    Date updated:
    12/11/2024
  • Attribution:
    Self
    Type of financial relationship:
    Independent contractor
    Ineligible company:
    Coherus
    Topic:
    pegfilgrastim biosimilar
    Date added:
    03/17/2022
    Date updated:
    12/11/2024

Pages

Return to Northern California Hematology Oncology Conference: A Tumor Board Case-Based Approach to the Latest Breakthroughs